My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday ↗

April 16, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday.

Via Benzinga

Topics Stocks

Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results ↗

April 16, 2024

Intra-Cellular Therapies is trying to position its antipsychotic in depression treatment.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 16, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

April 04, 2024

Via Benzinga

8 Analysts Assess Intra-Cellular Therapies: What You Need To Know ↗

April 03, 2024

Via Benzinga

Where Intra-Cellular Therapies Stands With Analysts ↗

February 23, 2024

Via Benzinga

Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies ↗

January 18, 2024

Via Benzinga

In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies ↗

January 02, 2024

Via Benzinga

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 21, 2024

Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

December 14, 2023

Via Benzinga

Expert Ratings for Intra-Cellular Therapies ↗

December 11, 2023

Via Benzinga

Are These Biotechs Ready To Launch? ↗

December 09, 2023

Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...

Via Talk Markets

Intra-Cellular Therapies's Earnings: A Preview ↗

November 01, 2023

Via Benzinga

What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies ↗

August 22, 2023

Via Benzinga

Analyst Expectations for Intra-Cellular Therapies's Future ↗

August 03, 2023

Via Benzinga

Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know ↗

July 06, 2023

Via Benzinga

Analyst Expectations for Intra-Cellular Therapies's Future ↗

June 22, 2023

Via Benzinga

Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data ↗

July 06, 2023

Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are...

Via Benzinga

Analyst Expectations for Intra-Cellular Therapies's Future ↗

June 05, 2023

Via Benzinga

Recap: Intra-Cellular Therapies Q1 Earnings ↗

May 04, 2023

Via Benzinga

A Preview Of Intra-Cellular Therapies's Earnings ↗

May 03, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

April 07, 2023

Via Benzinga

Analyst Ratings for Intra-Cellular Therapies ↗

March 29, 2023

Via Benzinga

Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

March 29, 2023

Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday.

Via Benzinga

Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features ↗

March 28, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023 ↗

April 20, 2023

Via Benzinga

Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 28, 2023

Gainers

Via Benzinga

Why Intra-Cellular Therapies Climbed Tuesday ↗

March 28, 2023

The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.

Via The Motley Fool

Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted ↗

March 28, 2023

The company believes it may have the answer for patients with "mixed features."

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 28, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.